Lithium Salvage: a step-change in UK battery recycling and manufacturing using (Weee-EV) - to establish the UKs first Lithium-ion Battery (LIB) recycling process.

锂回收:英国使用 (Weee-EV) 电池回收和制造的重大变革 - 建立英国第一个锂离子电池 (LIB) 回收流程。

基本信息

  • 批准号:
    10058907
  • 负责人:
  • 金额:
    $ 94.56万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Launchpad
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

In the UK, 235,000 tonnes of Lithium-ion Batteries (LIBs) derived from Electric Vehicles are expected to reach end-of-life by 2040\. Additionally, planned Gigafactories are expected to produce up to 15 kt/year of scrap. LIBs are increasingly found in consumer products (e.g. hoovers, lawn mowers) with a predicted 140,000 tonnes of consumer LIBs reaching end-of-life by 2025\.Yet the UK loses £13.63m/year from waste electricals/batteries due to lack of advanced recovery technologies \[MaterialFocus,2021\], threatening 114,000 direct automotive jobs linked to Gigafactory potential by 2040 \[T&E,2021\]. Currently all UK end-of-life LIBs are exported to Europe for pyrometallurgical-based recycling, consuming large amounts of energy and resulting in environmental emissions. Not all materials are recovered, specifically graphite and lithium, now listed as critical raw materials by the UK government (high risk of supply problems).Furthermore, under the EU Green Deal, all LIBs must contain minimum levels of recycled content by 2030, yet the UK has no on-shore supply of critical materials from recycled sources. This threatens the export capabilities of UK manufacturers.**Lithium Salvage (Li-Sal)** aims to establish the UKs first LIB recycling plant in the Tees Valley. Underpinned by cutting-edge fundamental research, they have developed a proof-of-concept for a low impact, clean and capital light recycling process that will maximise the quantity and quality of materials extracted from LIBs; and reclaim graphite and lithium. This project will deepen the industrial research required to demonstrate the optimum processes route, ensure systems scalability and commercial viability.Together with project partners from across the battery supply chain, Li-Sal is supported by: metals and materials experts from **Teesside University (TU)** and **Centre for Process Innovation (CPI)**; waste experts and feedstock suppliers **PA Moody Recycling (GAP);** and commodity market specialists **Pennine Energy**.Once built, the proposed facility will on-shore recycling in the UK and provide materials 'critical' to Gigafactory and renewable technology supply-chains. This will increase the attractiveness of the Tees Valley for up-stream investment in Gigafactories and provide a critical supply of materials required for a Net Zero Industrial Cluster in the Northeast of England. The proposed factory will create new jobs (with a significant job multiplier effect upstream and downstream of the plant), drive revenue and help delivery of the Governments levelling up agenda, whilst putting the UK at the forefront of sustainable recycling innovation, supporting the Net Zero by 2050 journey.
在英国,预计到2040年,来自电动汽车的23.5万吨锂离子电池(lib)将达到使用寿命。此外,计划中的gigafactory预计每年将生产高达1.5万吨的废钢。越来越多的消费者产品(如吸尘器、割草机)中发现了锂离子电池,预计到2025Ẏet将有14万吨消费者锂离子电池报废,由于缺乏先进的回收技术\[MaterialFocus,2021\],英国每年因废电器/电池损失1363万英镑,到2040年将威胁到114,000个与Gigafactory潜力相关的直接汽车工作\[T&E,2021\]。目前,英国所有报废的lib都出口到欧洲进行基于火法冶金的回收,消耗大量能源并导致环境排放。并不是所有的材料都被回收,特别是石墨和锂,现在被英国政府列为关键原材料(供应问题的高风险)。此外,根据欧盟绿色协议(EU Green Deal),到2030年,所有lib必须包含最低水平的回收成分,但英国没有来自回收资源的关键材料的岸上供应。这威胁到英国制造商的出口能力。**锂回收(Li-Sal)**旨在在蒂斯山谷建立英国第一家锂离子回收工厂。在前沿基础研究的支持下,他们开发了一种低影响、清洁和轻资本回收过程的概念验证,该过程将最大限度地提高从lib中提取的材料的数量和质量;回收石墨和锂。该项目将深化工业研究,以证明最佳的工艺路线,确保系统的可扩展性和商业可行性。与来自整个电池供应链的项目合作伙伴一起,Li-Sal得到了来自**提赛德大学(TU)**和**工艺创新中心(CPI)**的金属和材料专家的支持;废物专家和原料供应商**PA穆迪回收(GAP);**和商品市场专家**Pennine Energy**。一旦建成,拟议中的设施将在英国进行岸上回收,并为Gigafactory和可再生技术供应链提供“关键”材料。这将增加蒂斯山谷对超级工厂上游投资的吸引力,并为英格兰东北部的净零排放产业集群提供所需的关键材料供应。拟议中的工厂将创造新的就业机会(对工厂的上游和下游都有显著的就业乘数效应),增加收入,帮助政府实现升级议程,同时使英国处于可持续回收创新的前沿,支持到2050年实现净零排放。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

其他文献

吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
生命分子工学・海洋生命工学研究室
生物分子工程/海洋生物技术实验室
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:

的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('', 18)}}的其他基金

An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
  • 批准号:
    2901954
  • 财政年份:
    2028
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
  • 批准号:
    2896097
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
  • 批准号:
    2780268
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
  • 批准号:
    2908918
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
  • 批准号:
    2908693
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
  • 批准号:
    2908917
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
  • 批准号:
    2879438
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
  • 批准号:
    2890513
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
  • 批准号:
    2879865
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
  • 批准号:
    2876993
  • 财政年份:
    2027
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Studentship

相似海外基金

Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
开发一种新型核苷挽救途径靶向小分子抑制剂来治疗克罗恩病
  • 批准号:
    10820782
  • 财政年份:
    2023
  • 资助金额:
    $ 94.56万
  • 项目类别:
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
开发一种新型核苷挽救途径靶向小分子抑制剂来治疗急性播散性脑脊髓炎 (ADEM)
  • 批准号:
    10755864
  • 财政年份:
    2023
  • 资助金额:
    $ 94.56万
  • 项目类别:
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy
端粒生物标志物可作为前列腺切除术后 PSA 升高的男性积极挽救治疗决策的工具
  • 批准号:
    10635291
  • 财政年份:
    2023
  • 资助金额:
    $ 94.56万
  • 项目类别:
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
开发一种新型核苷挽救途径靶向小分子抑制剂来治疗系统性红斑狼疮
  • 批准号:
    10755905
  • 财政年份:
    2023
  • 资助金额:
    $ 94.56万
  • 项目类别:
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types
开发一种新型的、靶向核苷酸挽救途径的小分子抑制剂来治疗治疗不足的肿瘤类型
  • 批准号:
    10697180
  • 财政年份:
    2023
  • 资助金额:
    $ 94.56万
  • 项目类别:
Regulation of nitrogen salvage in non-ruminants
非反刍动物氮回收的调控
  • 批准号:
    RGPIN-2017-05275
  • 财政年份:
    2022
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Discovery Grants Program - Individual
Adjuvant heat treatment for catheter salvage in central line associated bloodstream infection (HEATSAVE)
中心导管相关血流感染导管抢救的辅助热处理 (HEATSAVE)
  • 批准号:
    10440832
  • 财政年份:
    2022
  • 资助金额:
    $ 94.56万
  • 项目类别:
Adjuvant heat treatment for catheter salvage in central line associated bloodstream infection (HEATSAVE)
中心导管相关血流感染导管抢救的辅助热处理 (HEATSAVE)
  • 批准号:
    10620335
  • 财政年份:
    2022
  • 资助金额:
    $ 94.56万
  • 项目类别:
Prize 202209PJT - Early Career Award in Cancer: An international randomized trial on neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma versus definitive chemoradiotherapy with salvage surgery as needed - The NEEDS Trial
奖 202209PJT - 癌症早期职业奖:食管鳞状细胞癌新辅助放化疗与根治性放化疗(根据需要进行挽救手术)的国际随机试验 - NEEDS 试验
  • 批准号:
    477684
  • 财政年份:
    2022
  • 资助金额:
    $ 94.56万
  • 项目类别:
    Operating Grants
Novel Gene Therapy for Critical Limb Ischemia and Limb Salvage in Vascular Occlusive Disease
针对血管闭塞性疾病严重肢体缺血和保肢的新型基因疗法
  • 批准号:
    10722862
  • 财政年份:
    2022
  • 资助金额:
    $ 94.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了